Centene Corporation Company Profile (NYSE:CNC)

Centene Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNC."

Centene Corporation (NYSE:CNC) released its quarterly earnings data on Tuesday, July, 25th. The company reported $1.59 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.30 by $0.29. The company earned $11.95 billion during the quarter, compared to analyst estimates of $11.69 billion. Centene Corporation had a net margin of 1.72% and a return on equity of 14.62%. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.29 earnings per share. View Centene Corporation's Earnings History.

Centene Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Centene Corporation.

Centene Corporation updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of $4.70-5.06 for the period, compared to the Thomson Reuters consensus estimate of $4.79. The company issued revenue guidance of $46.4-47.2 billion, compared to the consensus revenue estimate of $46.82 billion.

18 brokers have issued twelve-month price objectives for Centene Corporation's shares. Their predictions range from $69.00 to $120.00. On average, they anticipate Centene Corporation's share price to reach $94.94 in the next year. View Analyst Ratings for Centene Corporation.

Here are some recent quotes from research analysts about Centene Corporation stock:

• 1. According to Zacks Investment Research, "Year to date, Centene’s shares have outperformed the industry. The company’s strong and consistent performance is likely to have generated confidence among the investors. It has seen substantial inorganic growth in the last five years. The acquisition of Health Net in 2016 bolstered the company’s growth, expansion and asset base. Its solid financial position provides a major boost to its capital deployment initiatives. The company’s strong Managed care segment also contributes to its strong results. The stock has seen the Zacks Consensus Estimate for the current year being revised upward by 3.4% in the last 60 days." (9/15/2017)
• 2. Cantor Fitzgerald analysts commented, "This morning, CNC reported 2Q17 results. Revenue of $11.95 billion was slightly ahead of FactSet consensus. Adjusted EPS was $1.59 vs. our estimate of $1.25 and consensus of $1.30." (7/25/2017)
• 3. Leerink Swann analysts commented, "We reiterate our Market Perform rating on CNC while raising PT to $64 from $62 after the 4Q report and almost 6% move up yesterday." (2/9/2017)

Some companies that are related to Centene Corporation include Zoetis (ZTS), McKesson Corporation (MCK), Alexion Pharmaceuticals (ALXN), Illumina (ILMN), Fresenius Medical Care Corporation (FMS), Actelion (ALIOF), Grifols, S.A. (GRFS), Astellas Pharma (ALPMY), Essilor International SA (ESLOY), Zimmer Biomet Holdings (ZBH), Cerner Corporation (CERN), Incyte Corporation (INCY), C.R. Bard (BCR), Edwards Lifesciences Corporation (EW), Quintiles Transitional Holdings (Q), Cardinal Health (CAH), Mylan N.V. (MYL) and AmerisourceBergen Corporation (Holding Co) (ABC).

Centene Corporation's management team includes the folowing people:

• Michael F. Neidorff, Chairman of the Board, President, Chief Executive Officer
• Jeffrey A. Schwaneke CPA, Chief Financial Officer, Executive Vice President, Treasurer
• Keith H. Williamson, Executive Vice President, General Counsel, Secretary
• Christopher D. Bowers, Executive Vice President - Marketing
• Cynthia J. Brinkley, Executive Vice President - Global Corporate Development
• Jesse N. Hunter, Executive Vice President - Products
• Christopher R. Isaak, Senior Vice President, Corporate Controller and Chief Accounting Officer
• Mark J. Brooks, Senior Vice President, Chief Information Officer
• Christopher A. Koster, Senior Vice President - Corporate Services
• Orlando Ayala, Independent Director

Centene Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include VANGUARD GROUP INC (10.11%), Robeco Institutional Asset Management B.V. (0.08%), Osborne Partners Capital Management LLC (0.06%), State Treasurer State of Michigan (0.03%), APG Asset Management N.V. (0.03%) and Assenagon Asset Management S.A. (0.02%). Company insiders that own Centene Corporation stock include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Institutional Ownership Trends for Centene Corporation.

Centene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Meeder Asset Management Inc., Tributary Capital Management LLC, State Treasurer State of Michigan, Fulton Bank N.A., Howe & Rusling Inc. and Osborne Partners Capital Management LLC. Company insiders that have sold Centene Corporation stock in the last year include Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Insider Buying and Selling for Centene Corporation.

Centene Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., APG Asset Management N.V., Wealth Enhancement Advisory Services LLC, Eqis Capital Management Inc. and Mutual of America Capital Management LLC. View Insider Buying and Selling for Centene Corporation.

Shares of Centene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Centene Corporation stock can currently be purchased for approximately $96.50.